作者
Elliott M Antman, Marc Cohen, David Radley, Carolyn McCabe, Janet Rush, Jerome Premmereur, Eugene Braunwald
发表日期
1999/10/12
期刊
Circulation
卷号
100
期号
15
页码范围
1602-1608
出版商
Lippincott Williams & Wilkins
简介
Background—Two phase III trials of enoxaparin for unstable angina/non–Q-wave myocardial infarction have shown it to be superior to unfractionated heparin for preventing a composite of death and cardiac ischemic events. A prospectively planned meta-analysis was performed to provide a more precise estimate of the effects of enoxaparin on multiple end points.
Methods and Results—Event rates for death, the composite end points of death/nonfatal myocardial infarction and death/nonfatal myocardial infarction/urgent revascularization, and major hemorrhage were extracted from the TIMI 11B and ESSENCE databases. Treatment effects at days 2, 8, 14, and 43 were expressed as the OR (and 95% CI) for enoxaparin versus unfractionated heparin. All heterogeneity tests for efficacy end points were negative, which suggests comparability of the findings in TIMI 11B and ESSENCE. Enoxaparin was associated …
引用总数
学术搜索中的文章
EM Antman, M Cohen, D Radley, C McCabe, J Rush… - Circulation, 1999
EM Antman, M Cohen, D Radley, C Mc Cabe, J Rush… - QUARTERLY JOURNAL OF CARDIOLOGY, 2000